Not provided
Not provided
Not provided
Not provided
Not provided
Principal investigator made the decision to close study and not submit a renewal. Lack of fixed research personnel to carry out the study effectively.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Vitiligo is an autoimmune cutaneous disorder that destroys melanocytes leading to depigmented areas of skin. In the United States, vitiligo affects 1% of patients, causing not only changes in the color of skin, but also significant cosmetic concerns and quality of life issues. Current treatment modalities, which include topical corticosteroids, intralesional corticosteroids, phototherapy, and systemic immunosuppression, are variably effective in inducing repigmentation. Unfortunately, some cases of vitiligo are refractory to treatment. There is a need for new, effective modalities to treat patients with otherwise refractory vitiligo.
Needling is an office based procedure that theoretically transposes healthy, pigmented skin cells to depigmented areas using a needle in vitiligo patients. Two preliminary studies of needling as a novel treatment for vitiligo had promising results but were limited by small sample size and subjective results.
The proposed randomized control trial (RCT) will further investigate the use of needling to treat vitiligo. It differs from the previous studies in that it seeks to identify the cause of clinical benefit by comparing needling alone to needling with corticosteroid, examines a larger number of patients, and quantifies improvement using confocal microscopy. Confocal microscopy (CFM) allows non-invasive visualization of the skin on a cellular level and has been used in the past to diagnose cutaneous pigmentary conditions. This study would be the first RCT of needling in vitiligo to use an objective measure to quantify results, thus has the potential to establish needling as a novel, effective treatment for vitiligo and to evaluate the utility of CFM for monitoring response to treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Needling | Active Comparator | Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch. Saline, which doesn't affect repigmentation in vitiligo, will be injected into the patch at multiple sites spaced approximately 1 cm apart with 0.1-0.2 cc of saline injected at each site. |
|
| Needling and Triamcinolone | Experimental | During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area. Triamcinolone (concentration: 2.5 mg/cc) will be injected into the patch at multiple sites spaced approximately 1 cm apart with 0.1-0.2 cc of triamcinolone injected at each site. |
|
| No treatment | No Intervention | No treatment will be done to these vitiligo patches as a control. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Needling | Procedure | Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch. |
| Measure | Description | Time Frame |
|---|---|---|
| Repigmentation of vitiligo patch using confocal microscopy | baseline | |
| Repigmentation of vitiligo patch using confocal microscopy | week 4 post treatment (only if repigmentation become first apparent at this time point) | |
| Repigmentation of vitiligo patch using confocal microscopy | week 8 post treatment (only if repigmentation become first apparent at this time point | |
| Repigmentation of vitiligo patch using confocal microscopy | week 12 post treatment (only if repigmentation become first apparent at this time point | |
| Repigmentation of vitiligo patch using confocal microscopy | week 16 post treatment (only if repigmentation become first apparent at this time point | |
| Repigmentation of vitiligo patch using confocal microscopy | week 20 post treatment (only if repigmentation become first apparent at this time point | |
| Repigmentation of vitiligo patch using confocal microscopy | week 24 post treatment (only if repigmentation become first apparent at this time point | |
| Repigmentation of vitiligo patch using confocal microscopy | week 28 post treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Photography measure to assess repigmentation | baseline | |
| Wood's lamp to assess repigmentation | baseline | |
| Photography measure to assess repigmentation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Babar Rao, MD | RWJUH Dermatology | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| RWJUH Dermatology office | Somerset | New Jersey | 08873 | United States |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Mar 14, 2019 | |
| Reset | Apr 4, 2019 | |
| Release | Jun 24, 2019 | |
| Reset | Jul 16, 2019 | |
| Release | Jan 21, 2021 | |
| Reset | Feb 10, 2021 | |
| Release | Feb 11, 2021 | |
| Reset | Mar 3, 2021 | |
| Release | Apr 12, 2021 | |
| Reset | May 5, 2021 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Mar 14, 2019 | Apr 4, 2019 | |||
| Jun 24, 2019 |
| ID | Term |
|---|---|
| D014820 | Vitiligo |
| ID | Term |
|---|---|
| D017496 | Hypopigmentation |
| D010859 | Pigmentation Disorders |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D014221 | Triamcinolone |
| D014222 | Triamcinolone Acetonide |
| ID | Term |
|---|---|
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Triamcinolone | Drug | During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area |
|
|
| week 4 post treatment |
| Photography measure to assess repigmentation | week 8 post treatment |
| Photography measure to assess repigmentation | week 12 post treatment |
| Photography measure to assess repigmentation | week 16 post treatment |
| Photography measure to assess repigmentation | week 20 post treatment |
| Photography measure to assess repigmentation | week 24 post treatment |
| Photography measure to assess repigmentation | week 28 post treatment |
| Wood's lamp to assess repigmentation | week 4 post treatment |
| Wood's lamp to assess repigmentation | week 8 post treatment |
| Wood's lamp to assess repigmentation | week 12 post treatment |
| Wood's lamp to assess repigmentation | week 16 post treatment |
| Wood's lamp to assess repigmentation | week 20 post treatment |
| Wood's lamp to assess repigmentation | week 24 post treatment |
| Wood's lamp to assess repigmentation | week 28 post treatment |
| Jul 16, 2019 |
| Jan 21, 2021 | Feb 10, 2021 |
| Feb 11, 2021 | Mar 3, 2021 |
| Apr 12, 2021 | May 5, 2021 |
| D011083 |
| Polycyclic Compounds |
| D013259 | Steroids, Fluorinated |